Cognetivity Neurosciences (STU:1UB) Ending Cash Position: €0.01 Mil (As of Oct. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cognetivity Neurosciences Ending Cash Position?

Cognetivity Neurosciences STU:1UB Ending Cash Position is €0.01 Mil as of Oct. 2023.

Cognetivity Neurosciences's Ending Cash Position for the quarter that ended in Oct. 2023 was €0.01 Mil.

Cognetivity Neurosciences's quarterly Ending Cash Position declined from Apr. 2023 (€0.49 Mil) to Jul. 2023 (€0.02 Mil) and declined from Jul. 2023 (€0.02 Mil) to Oct. 2023 (€0.01 Mil).

Cognetivity Neurosciences's annual Ending Cash Position increased from Jan. 2021 (€0.88 Mil) to Jan. 2022 (€0.96 Mil) and increased from Jan. 2022 (€0.96 Mil) to Jan. 2023 (€1.55 Mil).

Cognetivity Neurosciences Ending Cash Position Related Terms

Cognetivity Neurosciences Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Cognetivity Neurosciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cognetivity Neurosciences Ending Cash Position Chart

Cognetivity Neurosciences Annual Data
Trend Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23
Ending Cash Position
Get a 7-Day Free Trial 0.17 0.40 0.88 0.96 1.55

Cognetivity Neurosciences Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.06 1.55 0.49 0.02 0.01

Cognetivity Neurosciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Cognetivity Neurosciences's Ending Cash Position for the fiscal year that ended in Jan. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.952+0.6
=1.55

Cognetivity Neurosciences's Ending Cash Position for the quarter that ended in Oct. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.021+-0.009
=0.01

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €0.01 Mil mean?
Cognetivity Neurosciences (STU:1UB) has a Ending Cash Position of €0.01 Mil as of Oct. 2023. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Cognetivity Neurosciences and its competitors.
Is Cognetivity Neurosciences' Ending Cash Position too high?
Cognetivity Neurosciences' current Ending Cash Position is €0.01 Mil.
How does Cognetivity Neurosciences' Ending Cash Position compare to VEEV and GEHC?
Cognetivity Neurosciences' Ending Cash Position of €0.01 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Healthcare Providers & Services company?
A good Ending Cash Position depends on the Healthcare Providers & Services industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Cognetivity Neurosciences and its competitors. Cognetivity Neurosciences's current Ending Cash Position is €0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cognetivity Neurosciences stock overvalued right now?
Cognetivity Neurosciences (STU:1UB) has a current Ending Cash Position of €0.01 Mil. The current Ending Cash Position is €0.01 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Cognetivity Neurosciences (STU:1UB), the current Ending Cash Position is €0.01 Mil as of Oct. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cognetivity Neurosciences Business Description

Address 800 West Pender Street, Suite 1430, Vancouver, BC, CAN, V6C 2V6
Cognetivity Neurosciences Ltd is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial, and consumer environments for potentially allowing early diagnosis of dementia. The Company is considered operating in one segment for development of the ICA platform. Its geographical areas include Canada, United Kingdom and Dubai.